Calliditas Therapeutics AB (CALT)
21.88
+0.38
(+1.77%)
USD |
NASDAQ |
May 22, 16:00
21.88
0.00 (0.00%)
After-Hours: 20:00
Calliditas Therapeutics Net Income (TTM): -26.43M for Dec. 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -26.43M |
| September 30, 2023 | -25.57M |
| June 30, 2023 | -29.63M |
| December 31, 2022 | -43.11M |
| September 30, 2022 | -67.58M |
| June 30, 2022 | -65.48M |
| March 31, 2022 | -64.95M |
| December 31, 2021 | -58.35M |
| September 30, 2021 | -53.36M |
| June 30, 2021 | -70.17M |
| March 31, 2021 | -57.39M |
| December 31, 2020 | -48.38M |
| Date | Value |
|---|---|
| September 30, 2020 | -30.96M |
| June 30, 2020 | -20.60M |
| March 31, 2020 | -5.452M |
| December 31, 2019 | -3.471M |
| September 30, 2019 | -5.958M |
| June 30, 2019 | -4.238M |
| March 31, 2019 | -15.14M |
| December 31, 2018 | -15.22M |
| September 30, 2018 | -15.20M |
| June 30, 2018 | -13.95M |
| March 31, 2018 | -13.68M |
| December 31, 2017 | -10.28M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-70.17M
Minimum
Jun 2021
-3.471M
Maximum
Dec 2019
-37.84M
Average
-37.03M
Median
Net Income (TTM) Benchmarks
| DBV Technologies SA | -79.51M |
| Cellectis SA | -101.07M |
| Adaptimmune Therapeutics PLC | -163.41M |
| Akari Therapeutics PLC | -14.24M |
| Biodexa Pharmaceuticals Plc | -8.826M |